2023 ASGCT Annual Meeting
Visit GenScript at Booth #349

Abstract: Current good manufacturing practice (cGMP) reagents should be used prior to IND enabling studies and clinical trials of novel cell and gene engineering therapies. However, rapid investment in cell therapy research has created a bottleneck in cGMP manufacturing capacity that threatens to delay many emerging therapeutic pipelines.

GenScript now supports non-viral cell and gene therapy development with cGMP manufacturing of synthetic CRISPR single guide RNA (sgRNA), Cas9 protein, and HDR knock-in templates. Our recently opened state-of-the-art manufacturing facility operates dedicated cGMP production lines to reliably provide both the material and necessary documentation required for successful IND submission and clinical trials.

GenScript offers phase-specific CRISPR gene editing solutions with the flexibility, expertise, and capacity to support projects at any stage, accelerating your therapeutic pipeline from early-phase research to clinical applications.

Abstract: The field of biomedical research is currently focused on personalized medicine and has made significant progress in cell and gene therapy. Both therapies aim to treat, prevent, or potentially cure diseases. While they share a common goal, they work differently and use different techniques.

The process of cell therapy entails the transplantation of healthy cells into the body, while gene therapy involves the introduction or modification of genetic material. The integration of these therapies has given rise to a new era of personalized medicine, enabling the creation of powerful treatments for specific diseases. One treatment that exemplifies this approach is CAR-T/NK cell therapy, where cell engineering is utilized for both Autologous and Allogeneic cell therapies. Additionally, Stem cells can be modified to address genetic conditions.

To support developers of cell and gene therapy, GenScript offers high-quality services, reagents, and instruments. This presentation will cover our comprehensive solutions for cell therapy and an overview of GenScript's cell engineering/gene editing portfolio and expertise.